^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study

Excerpt:
The remaining three mutants (M351T, H396P and M244V) in ABL kinase structure are located away from ponatinib binding site but are inhibited by ponatinib.
DOI:
https://dx.doi.org/10.1371%2Fjournal.pone.0078556